We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us


EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App

Antiphospholipid Antibodies in Patients With Unexplained Articular Manifestations

By LabMedica International staff writers
Posted on 21 Dec 2022
Print article
Image: The SFRI IRE 96 is a simple and robust ELISA Absorbance Microplate Reader finds application in ELISA assays (Photo courtesy of HealthManagement.org)
Image: The SFRI IRE 96 is a simple and robust ELISA Absorbance Microplate Reader finds application in ELISA assays (Photo courtesy of HealthManagement.org)

Joint pain is the most common chronic pain making it one of the largest causes of disabilities in the world. Arthritis is a frequent condition that causes edema, redness, heat, loss of function and pain. It can affect one or more joints and there exist more than 100 different types.

Antiphospholipid antibodies (aPL) represent a complex and heterogeneous group of antibodies directed against anionic phospholipids or protein-phospholipid complexes. Persistent aPL have been associated with antiphospholipid syndrome (APS), which is defined by the presence of recurrent venous and/or arterial thrombosis and often pregnancy morbidity.

Immunologists at the Farhat Hached Hospital (Sousse, Tunisia) and their colleagues conducted a retrospective study including 313 patients suffering from arthritis or arthralgia without evident cause. Serum samples were collected from January 2017 to December 2019. Antinuclear antibodies (ANA), rheumatoid factors (RF) and anti-cyclic citrullinated peptides antibodies (CCP-Ab) were negative for all patients. Sera of 266 healthy blood donors (HBD) were included as normal controls.

The team detected aCL-IgG and IgM using an enzyme-linked immunosorbent assay (ELISA) kit and aCL-IgA were assessed by ELISA kit (Orgentec Diagnostika, Mainz, Germany). Highly purified cardiolipin was coated on microwells with β2GPI. Specific antibodies in the patient sample bound to antigen. microtiter plate reader and results were detected with an IRE 96microtiter plate reader (SFRI Medical Diagnostics, Saint Jean d'Illac, France). The scientists evaluated aβ2GPI-IgG and IgM by an ELISA kit (Orgentec Diagnostika) using a purified human β2GPI. aβ2GPI-IgA were assessed by ELISA kit. RF IgG, IgM and IgA were assessed using a three commercially ELISA kits, (Orgentec Diagnostika). CCP-Ab were measured by an available second-generation ELISA and ANA were detected by indirect immunofluorescence on HEp-2 cells (Euroimmun, Luebeck, Germany).

The investigators reported that out of the 313 patients, 250 were females and 63 were males. The mean age of patients was 49 ± 14 years (17–87 years). One hundred eleven patients have arthralgia and 202 have arthritis. The frequency of aCL and/or aβ2GPI (24.9%) was significantly higher in patients than in HBD (10.9%). The frequency of aβ2GPI was 23.6% in patients and 9.4% in the control group. aβ2GPI-IgA was significantly more frequent in patients than in the control group (20.4% versus 7.5%. aβ2GPI was most commonly observed than aCL in patients (23.6% versus 6.4%. IgA isotype of aβ2GPI was the most frequent in 20.4% of patients while IgG and IgM were detected in 5.4% and 2.9% respectively.

The authors concluded that they had demonstrated an elevated frequency of aβ2GPI-IgA in patients with unexplained arthralgia or arthritis. The possible pathogenic mechanism of aβ2GPI remained to be demonstrated and a prospective study is necessary to known if aβ2GPI-IgA will persist over time. The study was published on December 13, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Farhat Hached Hospital
Orgentec Diagnostika
SFRI Medical Diagnostics

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.